Following up on a strong earnings report from Wednesday, hi-tech glassmaker Corning (NYSE:GLW) offered further details this morning on its plans for the future.
Specifically, Corning announced plans to capitalize upon a coming wave in new environmental regulation of heavy-duty engines in Europe and China, by investing similarly heavily in its production of diesel emissions control products.
Corning says it will spend about $250 million on capital improvements in its Environmental Technologies & Life Sciences Business Group, hoping to double its revenues from the group by 2017. Corning will spend to increase capacity at its Erwin diesel facility, which manufactures large ceramic substrates and filters for heavy-duty diesel engine, truck, construction, and agricultural equipment manufacturers.
However, all this new spending will not affect Corning's forecast for 2013 capital expenditures, the company assured investors. Yesterday, Corning pegged 2013 capex spending at approximately $1.3 billion, down from last year's $1.8 billion. With investments in clean diesel being spread out over the next three years, Corning has already figured this investment into capital spending projections for 2013 and 2014. The company gave no such assurances for 2015, however, when the expanded diesel facilities should go into operation.
Fool contributor Rich Smith has no position in any stocks mentioned. The Motley Fool recommends Corning. The Motley Fool owns shares of Corning. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why the Apple Inc. iPhone X Isn't Doing as Well as Hoped in China
The answer might surprise you.
3 Signs You're Better Off Delaying Retirement
If you're coping with any of the issues below, then retiring now is probably a bad idea.
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Which stock wins in a head-to-head match-up between the big biotech and the big pharma company?